Lycia Therapeutics
LYTAC degrader platform for targeted protein degradation of extracellular and circulating proteins
- Sector
- Biotech
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Founded
- 2019
- Latest Form D
- $75M, Jun 2026
- Total capital
- $277M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $277M
- 4 Form D · last Jun 2026
- 4 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 39 pending · first 2025
- Rank in peer group#481 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 4th filing$75M
- Private capital raisedForm D · SEC · 3rd filing$107M
- Private capital raisedForm D · SEC · 2nd filing$70.1M
- Private capital raisedForm D · SEC · 1st filing$25.4M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#481 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Aetna Wun TrombleyExecutive Officer, DirectorNamed in SEC Form D filings
- Amy BachrodtExecutive OfficerNamed in SEC Form D filings
- Andrew GottesdienerDirectorNamed in SEC Form D filings
- Clare OzawaDirectorNamed in SEC Form D filings
- Jeremy S. CaldwellExecutive Officer, DirectorNamed in SEC Form D filings
- Laurent S. FischerDirectorNamed in SEC Form D filings
Show all 10 people
- Ming FangDirectorNamed in SEC Form D filings
- Thomas WoiwodeDirectorNamed in SEC Form D filings
- Tim AndersonDirectorNamed in SEC Form D filings
- William RieflinDirectorNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 40- PendingBispecific Antibodies And Constructs For Lysosomal Targeting Degradation And Methods Of Use ThereofUSPTOApplication 19103204
- PendingBifunctional Folate Receptor Binding CompoundsUSPTOApplication 18568779
- PendingAsgpr Cell Surface Receptor Binding Compounds And ConjugatesUSPTOApplication 18974654
Show all 40 patent records
- Bispecific Antibodies And Constructs For Lysosomal Targeting Degradation And Methods Of Use ThereofFeb 26, 2026 · Application 19103204Pending
- Bifunctional Folate Receptor Binding CompoundsApr 24, 2025 · Application 18568779Pending
- Asgpr Cell Surface Receptor Binding Compounds And ConjugatesMar 27, 2025 · Application 18974654Pending
- Asgpr Cell Surface Receptor Binding Compounds And ConjugatesMar 25, 2025 · US 12,258,332Granted
- M6PR Cell Surface Receptor Binding Compounds And ConjugatesOct 10, 2024 · Application 18578293Pending
- Bifunctional Compounds Containing IGF-2 PolypeptidesAug 22, 2024 · Application 18568767Pending
- Bifunctional Folate Receptor Binding CompoundsMay 23, 2024 · Application 18271230Pending
- Modified Viral Compositions For Viral TransductionSep 7, 2023 · Application 18012838Pending
- Bifunctional Bridging Compositions For Viral TransductionJul 20, 2023 · Application 18012840Pending
- Cell Surface Receptor Binding Compounds and ConjugatesMay 25, 2023 · Application 17792027Pending
- Lysosomal Targeting Bifunctional Molecules For Degradation Of Thyroid Stimulating Hormone Receptor AutoantibodiesApplication 63571393Pending
- Asgpr Binding Compounds And ConjugatesApplication PCTUS2024011898Pending
- M6PR Binding Compounds And ConjugatesApplication PCTUS2024011899Pending
- Cycling Lysosomal Targeting Antibody ConjugatesApplication PCTUS2024011897Pending
- Lysosomal Targeting Bifunctional Molecules For Degradation Of AutoantibodiesApplication PCTUS2024011901Pending
- Bispecific Antibodies And Constructs For Lysosomal Targeting Degradation And Methods Of Use ThereofApplication PCTUS2023030120Pending
- Lysosomal Targeting Bifunctional Molecules For Degradation Of Muscle-specific Kinase AutoantibodiesApplication 63518541Pending
- Asgpr Binding Compounds And ConjugatesApplication 63518532Pending
- Lysosomal Targeting Bifunctional Molecules for Degradation of AutoantibodiesApplication 63518537Pending
- Asgpr Binding Compounds And ConjugatesApplication 19148577Pending
- Lysosomal Targeting Bifunctional Molecules For Degradation Of AutoantibodiesApplication 63480509Pending
- M6PR Binding Compounds And ConjugatesApplication 63439806Pending
- Lysosomal Targeting Bifunctional Molecules For DegradationApplication 63480510Pending
- Asgpr Binding Compounds And ConjugatesApplication 63439811Pending
- Bispecific Antibodies and Constructs for Lysosomal Targeting Degradation and Methods of Use ThereofApplication 63397751Pending
- M6PR Cell Surface Receptor Binding Compounds And ConjugatesApplication PCTUS2022037196Pending
- Asgpr Cell Surface Receptor Binding Compounds And ConjugatesApplication PCTUS2022037227Pending
- Bifunctional Folate Receptor Binding CompoundsApplication PCTUS2022073164Pending
- Bifunctional Compounds Containing IGF-2 PolypeptidesApplication PCTUS2022034777Pending
- Bifunctional Folate Receptor Binding CompoundsApplication PCTUS2022011857Pending
- M6PR Cell Surface Receptor Binding Compounds And ConjugatesApplication 63221915Pending
- Asgpr Cell Surface Receptor Binding Compounds And ConjugatesApplication 63221918Pending
- Bifunctional Bridging Compoistions For Viral TransductionApplication PCTUS2021039010Pending
- Modified Viral Compositions For Viral TransductionApplication PCTUS2021039011Pending
- Lysosome-targeting Bifunctional Compounds For Degrading Tnf-alphaApplication 63214773Pending
- Bifunctional Folate Receptor Binding CompoundsApplication 63214774Pending
- IGF-2 Polypeptide Containing Modified Viral CompositionsApplication 63214015Pending
- IGF-2 Polypeptide Containing Bifunctional Compounds For Viral TransductionApplication 63214169Pending
- Bifunctional Compounds Containing IGF-2 PolypeptidesApplication 63214004Pending
- Novel Viral Compositions And Methods Of UseApplication 63135527Pending
Related companies, and why
- ALKEUS PHARMACEUTICALS, INC.Similar federal contract value in Biotech · null in contracts
- IMMUNIC, INC.Similar federal contract value in Biotech · null in contracts
- IRONWOOD PHARMACEUTICALS INCSimilar federal contract value in Biotech · null in contracts
- BioNTech SESimilar federal contract value in Biotech · null in contracts
- Attralus, Inc.Similar federal contract value in Biotech · null in contracts
- NEONC TECHNOLOGIES HOLDINGS, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .